Novo Nordisk A/S Common Stock (NVO)

In a decisive show of confidence for the biotechnology sector, institutional heavyweights have significantly ramped up their positions in Amgen (NASDAQ: AMGN) throughout the first quarter of 2026. Regulatory filings and recent market data indicate a coordinated accumulation by major asset managers, who are increasingly viewing the California-based biotech giant

One of these assets is catalyst-driven; the other isn't.

A catalyst for stock performance may be just ahead.

This company has a habit of beating the market over long periods.

The Wegovy pill could change Hims & Hers' growth in 2026.

The healthcare stock has lost more than half of its value in the past year.

Eli Lilly's GLP-1 drugs are leaders in a new and exciting drug category, but investors already know this fact.

I am not turned off by the company's recent setbacks.

As of March 18, 2026, Hims & Hers Health (NYSE: HIMS) has reclaimed its position as the primary protagonist in the direct-to-consumer (DTC) healthcare narrative. Following a turbulent start to the year characterized by regulatory uncertainty and legal skirmishes, the company’s stock staged a breathtaking 50%+ rally in the first two weeks of March. This [...]

Even on a budget, you can get quality stocks.

The company stated that people who sign up for the waitlist will gain priority access to the official debut of Ozempic and Wegovy on the telehealth company’s platform.

Each of these companies could benefit from this high-growth market over time.

These companies are benefiting from a tidal wave of demand for new weight-loss drugs.

The analyst’s new price target represents a potential downside of about 14% from the stock’s last closing price on Monday.

Eli Lilly's stock price is based on growth rates that might fall short.

Novo Nordisk recently announced promising trial results for one of its GLP-1 drugs in development.

Pfizer has reached a turning point.

The drama and uncertainty around Novo Nordisk and Hims & Hers Health might finally be ending.

Despite continued volatility, stocks have stayed resilient as investors navigate the fog of war. The story is largely about oil. When the price of crude oil goes up, stocks go down and vice versa. However, the larger word is uncertainty. Specifically, how long will the conflict continue, and what will normal look like for energy prices when it’s over?

It won't be easy to knock the company off its pedestal.

As the old adage goes, cheap stocks are cheap for a reason. But the reason might not be a good one.

As of March 13, 2026, the healthcare landscape has witnessed one of the most significant pivots in the history of digital health. Hims & Hers Health, Inc. (NYSE: HIMS) has officially transitioned from a controversial provider of compounded GLP-1 medications to a cornerstone of the global pharmaceutical distribution network. The catalyst for this transformation was [...]

Not many things have gone right for Novo Nordisk recently, but this is one of them.